The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

HHS is taking “immediate steps” to implement President Donald Trump’s executive order, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients — a key initiative aimed at ...

Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...

According to the timeline in the May 12 executive order, prescription drug price reductions would not happen "almost ...

Economists begin by asking what would happen in a completely free market. Then we ask whether government intervention of some ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting ... cash into research and development for diseases ...

Ostensibly, the “end the pill penalty” campaign is about protecting the development ... drugs from seven years to 11 years, with the extended time period benefiting drugmakers’ bottom line. ...

Industry officials told WSJ the disruptions are leading to longer drug ... costs for drugmakers, particularly smaller biotechs that rely on timely FDA decisions to maintain funding and hit ...

Tax credits, an accelerated regulatory approval pathway, higher relative overall success rates (i.e., investigational new drug filing to regulatory approval), exemptions from user fees, and periods of ...